| Literature DB >> 24861547 |
Xiang Mei Kong1, Wen Qing Zhu1, Jia Xu Hong1, Xing Huai Sun2.
Abstract
OBJECTIVE: To investigate whether understanding of glaucoma is associated with psychological disturbance and vision-related quality of life (QoL) in patients with glaucoma.Entities:
Mesh:
Year: 2014 PMID: 24861547 PMCID: PMC4039808 DOI: 10.1136/bmjopen-2013-004632
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Sociodemographic and clinical characteristics of subjects
| Variable | Mean±SD, range | N=500 |
|---|---|---|
| Age, years | 56.46±17.22 (18–91) | |
| 18–40 | 96 | |
| 41–60 | 148 | |
| >60 | 256 | |
| Gender | ||
| Male | 266 | |
| Female | 234 | |
| Educational level | ||
| Primary school | 37 | |
| Middle school | 260 | |
| University and above | 203 | |
| Living status | ||
| Living alone | 31 | |
| Living with family | 469 | |
| Marital status | ||
| Unmarried | 45 | |
| Married | 437 | |
| Divorced | 2 | |
| Single | 16 | |
| Duration of glaucoma, years | 4.64±6.30 (0.10–37.00) | |
| <1 | 132 | |
| 1–5 | 203 | |
| >5 | 165 | |
| Type of glaucoma | ||
| POAG | 271 | |
| PACG | 186 | |
| SG | 43 | |
| Medication | ||
| 0 | 73 | |
| 1 type | 174 | |
| 2 types | 166 | |
| 3 or more types | 87 | |
| Laser treatment | ||
| No | 421 | |
| Yes | 79 | |
| Surgical treatment | ||
| No | 276 | |
| Yes | 224 | |
| SGC member | ||
| No | 319 | |
| Yes | 181 | |
| BCVA of better-seeing eye | 0.21±0.34 (−1.30 to 2.60) | |
| >20/40 | 343 | |
| 20/200–20/40 | 140 | |
| <20/200 | 17 | |
| BCVA of worse-seeing eye | 0.80±0.94 (0.18–3.20) | |
| >20/40 | 176 | |
| 20/200–20/40 | 183 | |
| <20/200 | 141 | |
| Lower IOP in both eyes, mm Hg | 15.93±5.33 (5.00–53.70) | |
| <18 | 346 | |
| 18–30 | 141 | |
| >30 | 13 | |
| Higher IOP in both eyes, mm Hg | 20.65±9.43 (7.00–65.00) | |
| <18 | 225 | |
| 18–30 | 206 | |
| >30 | 69 | |
| MD of less-damaged eye, dB | −7.73±6.27 (−30.52 to 2.70) | |
| >−10 | 370 | |
| −10 to −20 | 97 | |
| <−20 | 33 | |
| MD of most-damaged eye, dB | −15.01±9.40 (−34.00 to 0.70) | |
| >−10 | 197 | |
| −10 to −20 | 145 | |
| <−20 | 158 | |
BCVA, best corrected visual acuity; IOP, intraocular pressure; MD, mean deviation; PACG, primary angle closure glaucoma; POAG, primary open angle glaucoma; SG, secondary glaucoma; SGC, Shanghai Glaucoma Club.
Scores for each subscale and total scale of the comprehension questionnaire, HADS and NEI VFQ-25 in all subjects
| Subscale | N | Mean | SD | Range | Rank |
|---|---|---|---|---|---|
| Comprehension questionnaire | |||||
| Knowledge of glaucoma | 500 | 7.30 | 3.27 | 0–12 | 2 |
| Compliance | 500 | 9.21 | 2.10 | 2–12 | 1 |
| Habits | 500 | 4.79 | 1.48 | 0–7 | 3 |
| Total comprehension | 500 | 21.30 | 5.78 | 6–31 | – |
| HADS questionnaire | |||||
| HADS-A | 500 | 6.12 | 3.64 | 0–18 | 2 |
| HADS-D | 500 | 7.29 | 4.18 | 0–18 | 1 |
| HADS | 500 | 13.41 | 6.59 | 0–32 | – |
| NEI VFQ-25 questionnaire | |||||
| General health | 500 | 66.58 | 15.48 | 0–100 | 7 |
| General vision | 500 | 52.41 | 18.80 | 0–100 | 11 |
| Ocular pain | 500 | 66.58 | 18.59 | 12.5–100 | 7 |
| Near activity | 500 | 70.80 | 26.57 | 0–100 | 5 |
| Distance activity | 500 | 72.40 | 26.15 | 0–100 | 4 |
| Social function | 500 | 86.75 | 19.82 | 0–100 | 2 |
| Mental health | 500 | 64.46 | 19.97 | 6.25–100 | 9 |
| Role difficulties | 500 | 54.63 | 25.00 | 0–100 | 10 |
| Dependency | 500 | 68.95 | 24.78 | 0–100 | 6 |
| Driving | 150 | 20.01 | 34.46 | 0–100 | 12 |
| Colour vision | 500 | 87.60 | 22.96 | 0–100 | 1 |
| Peripheral vision | 500 | 84.55 | 19.83 | 0–100 | 3 |
| Composite score | 500 | 70.60 | 15.38 | 16.40–97.16 | – |
HADS, Hospital Anxiety and Depression Scale; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression Scale-Depression; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire.
Multivariate linear regression of subscales of HADS and NEI VFQ-25 according to the comprehension of patients with glaucoma
| Knowledge of glaucoma | Compliance | Habits | Total comprehension | |||||
|---|---|---|---|---|---|---|---|---|
| Subscale | β Coefficient (SE) | p Value | β Coefficient (SE) | p Value | β Coefficient (SE) | p Value | β Coefficient (SE) | p Value |
| HADS-A | ||||||||
| Model 1 | −0.0 (0.0) | 0.471 | −0.1 (0.1) | 0.238 | 0.0 (0.1) | 0.986 | −0.0 (0.0) | 0.405 |
| Model 2 | −0.1 (0.1) | 0.168 | −0.2 (0.1) | 0.058 | −0.2 (0.1) | 0.174 | −0.1 (0.0) | |
| Model 3 | −0.1 (0.1) | 0.244 | −0.1 (0.1) | 0.085 | −0.1 (0.1) | 0.258 | −0.1 (0.0) | 0.074 |
| HADS-D | ||||||||
| Model 1 | −0.5 (0.1) | −0.7 (0.1) | −1.1 (0.1) | −0.3 (0.0) | ||||
| Model 2 | −0.3 (0.1) | −0.4 (0.1) | −0.7 (0.1) | −0.2 (0.0) | ||||
| Model 3 | −0.2 (0.1) | −0.3 (0.1) | −0.7 (0.1) | −0.2 (0.0) | ||||
| HADS | ||||||||
| Model 1 | −0.5 (0.1) | −0.8 (0.1) | −1.1 (0.2) | −0.4 (0.0) | ||||
| Model 2 | −0.3 (0.1) | −0.5 (0.2) | −0.9 (0.2) | −0.3 (0.1) | ||||
| Model 3 | −0.3 (0.1) | −0.5 (0.1) | −0.8 (0.2) | −0.3 (0.1) | ||||
| General health | ||||||||
| Model 1 | 0.3 (0.2) | 0.154 | 0.5 (0.3) | 0.135 | 0.3 (0.5) | 0.500 | 0.2 (0.1) | 0.128 |
| Model 2 | 0.3 (0.3) | 0.259 | 0.4 (0.4) | 0.242 | 0.5 (0.5) | 0.358 | 0.2 (0.2) | 0.145 |
| Model 3 | 0.2 (0.3) | 0.463 | 0.3 (0.4) | 0.355 | 0.3 (0.5) | 0.542 | 0.2 (0.2) | 0.306 |
| General vision | ||||||||
| Model 1 | 0.9 (0.3) | 1.5 (0.4) | 1.6 (0.6) | 0.6 (0.1) | ||||
| Model 2 | 1.0 (0.3) | 1.4 (0.4) | 1.6 (0.6) | 0.8 (0.2) | ||||
| Model 3 | 0.7 (0.3) | 1.2 (0.4) | 1.2 (0.6) | 0.6 (0.2) | ||||
| Ocular pain | ||||||||
| Model 1 | 0.1 (0.3) | 0.597 | 0.1 (0.4) | 0.859 | 0.1 (0.6) | 0.872 | 0.1 (0.1) | 0.685 |
| Model 2 | 0.4 (0.3) | 0.222 | 0.1 (0.5) | 0.883 | 0.5 (0.6) | 0.428 | 0.2 (0.2) | 0.303 |
| Model 3 | 0.2 (0.3) | 0.590 | −0.1 (0.4) | 0.798 | 0.3 (0.6) | 0.662 | 0.1 (0.2) | 0.732 |
| Near activity | ||||||||
| Model 1 | 2.0 (0.4) | 3.0 (0.6) | 3.1 (0.8) | 1.3 (0.2) | ||||
| Model 2 | 1.5 (0.4) | 2.2 (0.6) | 2.5 (0.9) | 1.2 (0.3) | ||||
| Model 3 | 1.1 (0.4) | 1.8 (0.6) | 1.9 (0.8) | 0.9 (0.2) | ||||
| Distance activity | ||||||||
| Model 1 | 1.7 (0.3) | 2.7 (0.5) | 3.5 (0.8) | 1.1 (0.2) | ||||
| Model 2 | 1.3 (0.4) | 2.1 (0.6) | 3.3 (0.9) | 1.2 (0.3) | ||||
| Model 3 | 0.9 (0.4) | 1.7 (0.5) | 2.6 (0.8) | 0.9 (0.2) | ||||
| Social function | ||||||||
| Model 1 | 0.5 (0.3) | 0.067 | 1.0 (0.4) | 1.1 (0.6) | 0.069 | 0.4 (0.2) | ||
| Model 2 | 0.7 (0.3) | 1.2 (0.5) | 1.8 (0.7) | 0.6 (0.2) | ||||
| Model 3 | 0.4 (0.3) | 0.205 | 0.9 (0.4) | 1.3 (0.6) | 0.4 (0.2) | |||
| Mental health | ||||||||
| Model 1 | 0.1 (0.3) | 0.853 | −0.1 (0.4) | 0.834 | −0.1 (0.6) | 0.847 | −0.0 (0.2) | 0.984 |
| Model 2 | 0.3 (0.3) | 0.337 | 0.1 (0.5) | 0.766 | 0.9 (0.7) | 0.177 | 0.2 (0.2) | 0.267 |
| Model 3 | 0.2 (0.3) | 0.617 | −0.0 (0.5) | 0.956 | 0.6 (0.6) | 0.350 | 0.1 (0.2) | 0.577 |
| Role difficulties | ||||||||
| Model 1 | 0.0 (0.3) | 0.985 | −0.1 (0.5) | 0.880 | −0.4 (0.8) | 0.622 | −0.0 (0.2) | 0.865 |
| Model 2 | 0.8 (0.4) | 0.066 | 0.7 (0.6) | 0.266 | 0.7 (0.9) | 0.387 | 0.5 (0.3) | 0.066 |
| Model 3 | 0.5 (0.4) | 0.200 | 0.4 (0.6) | 0.451 | 0.3 (0.8) | 0.676 | 0.3 (0.3) | 0.225 |
| Dependency | ||||||||
| Model 1 | 0.6 (0.3) | 0.074 | −0.2 (0.5) | 0.773 | 0.4 (0.7) | 0.636 | 0.2 (0.2) | 0.304 |
| Model 2 | 0.5 (0.4) | 0.217 | −0.7 (0.6) | 0.253 | 0.7 (0.8) | 0.397 | 0.1 (0.3) | 0.618 |
| Model 3 | 0.5 (0.4) | 0.288 | −0.7 (0.6) | 0.230 | 0.7 (0.9) | 0.406 | 0.1 (0.3) | 0.716 |
| Colour vision | ||||||||
| Model 1 | 0.8 (0.3) | 1.3 (0.5) | 1.9 (0.7) | 0.6 (0.2) | ||||
| Model 2 | 0.9 (0.4) | 1.3 (0.6) | 2.4 (0.8) | 0.8 (0.2) | ||||
| Model 3 | 0.7 (0.4) | 0.080 | 1.1 (0.5) | 2.1 (0.8) | 0.7 (0.2) | |||
| Peripheral vision | ||||||||
| Model 1 | −0.2 (0.3) | 0.489 | 0.0 (0.4) | 0.965 | −0.2 (0.6) | 0.723 | −0.1 (0.2) | 0.641 |
| Model 2 | 0.3 (0.3) | 0.373 | 0.6 (0.5) | 0.189 | 1.2 (0.7) | 0.066 | 0.3 (0.2) | 0.098 |
| Model 3 | 0.0 (0.3) | 0.885 | 0.3 (0.4) | 0.417 | 0.8 (0.6) | 0.215 | 0.2 (0.2) | 0.414 |
| Composite score | ||||||||
| Model 1 | 0.6 (0.2) | 0.9 (0.3) | 1.0 (0.5) | 0.4 (0.1) | ||||
| Model 2 | 0.7 (0.3) | 0.8 (0.3) | 1.4 (0.5) | 0.5 (0.1) | ||||
| Model 3 | 0.5 (0.2) | 0.6 (0.3) | 0.051 | 1.1 (0.5) | 0.4 (0.1) | |||
Comprehension of glaucoma, compliance, habits and total comprehension were independent variables in the models. Model 1: crude; model 2: adjustment for age, gender, educational level, living status, marital status, duration of glaucoma, type of glaucoma, medication, past laser treatment and past surgical treatment; model 3: further adjustment for best corrected visual acuity of worse-seeing eye, higher intraocular pressure in both eyes, and mean deviation of visual field in worse-seeing eye based on model 2.
HADS, Hospital Anxiety and Depression Scale; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression Scale-Depression; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire.
Figure 1The association between level of comprehension and the subscores of the Hospital Anxiety and Depression Scale (HADS), HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) in Chinese patients with glaucoma. As the level of comprehension increased, the scores of HADS-D and total HADS decreased significantly (F=65.371, p<0.001; F=25.302, p<0.001, respectively), while the change in HADS-A was not significant (F=0.638, p=0.529).
Figure 2The association between level of comprehension and four of the subscores of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) in Chinese patients with glaucoma. As the level of comprehension increased, the subscores of general vision (F=8.372, p<0.001), near activity (F=16.607, p<0.001), far activity (F=12.884, p<0.001) and the NEI VFQ-25 composite score (F=3.821, p<0.05) increased dramatically.
Comparison of the HADS-D score and NEI VFQ-25 composite score by different levels of the subtypes of comprehension
| Subtype of comprehension | N | HADS-D | p Value | p1 Value | p2 Value | p3 Value | NEI VFQ-25 composite score | p Value | p1 Value | p2 Value | p3 Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Knowledge of glaucoma | 1.000 | 0.292 | 1.000 | 0.363 | 1.000 | ||||||
| Low | 234 | 9.06±4.00 | 69.64±15.85 | ||||||||
| Moderate | 169 | 5.89±3.72 | 70.83±15.23 | ||||||||
| High | 97 | 5.48±3.67 | 72.52±14.40 | ||||||||
| Compliance | 0.139 | 0.527 | 0.142 | 1.000 | |||||||
| Low | 105 | 9.31±4.11 | 68.21±15.59 | ||||||||
| Moderate | 230 | 7.61±4.18 | 70.66±14.92 | ||||||||
| High | 165 | 5.56±3.52 | 72.02±15.77 | ||||||||
| Habits | 0.327 | 0.066 | 0.276 | ||||||||
| Low | 175 | 9.38±4.18 | 67.40±16.54 | ||||||||
| Moderate | 140 | 6.56±3.81 | 73.95±13.82 | ||||||||
| High | 185 | 5.86±3.65 | 71.08±14.82 |
p Value: ANOVA; further compared by Bonferroni: p1: low versus moderate; p2: low versus high; p3: moderate versus high.
HADS-D, Hospital Anxiety and Depression Scale-Depression; NEI VFQ-25, 25-item National Eye Institute Visual Function Questionnaire.